You are here: Industry Insights > JNJ-78436735

News List

Johnson & Johnson’s COVID-19 vaccine safely elicits an immune response europeanpharmaceuticalreview
January 21, 2021
An interim analysis of Phase I/II trial data shows 90 percent of 18-55 year olds had a neutralising antibody response that lasts at least two months.
Janssen begins second Phase III Covid-19 vaccine trial pharmaceutical-technology
November 17, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J) has initiated enrolment and dosing of participants in the Phase III ENSEMBLE 2 trial of a two-dose regimen of JNJ-78436735, an investigational vaccine candidate for preventing Covid-19 ...
Second wave of COVID-19 vaccines may not be needed to reach higher efficacy bar than first batch expresspharma
October 26, 2020
It would be best for second wave vaccines to underscore ideal subpopulations or manufacturing and storage advantages that could underscore uptake.
J&J Initiates Phase III ENSEMBLE Trial for COVID-19 Vax contractpharma
September 24, 2020
Will enroll up to 60,000 volunteers across three continents to study the safety and efficacy of a single vaccine dose of JNJ-78436735 versus placebo.